✦ LIBER ✦

A transition of P2Y12antagonists for acute coronary syndrome: benefits, risks and costs

✍ Scribed by Wang, Wei Eric; Wang, Hongyong; Wang, Xukai; Zeng, Chunyu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ticagrelor: a P2Y 12 antagonist for use

✍ Wijeyeratne, Yanushi Dullewe; Joshi, Rashi; Heptinstall, Stan 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 978 KB

Ticagrelor: Oral Reversible P2Y12 Recept

✍ Judy W.M. Cheng 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 364 KB

P2Y12 Antagonists in Acute Coronary Synd

✍ Christopher W. Good; Peter B. Berger 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 143 KB

Combined Cardioprotectant and Antithromb

✍ Cohen, M. V.; Downey, J. M. 📂 Article 📅 2013 🏛 SAGE Publications 🌐 English ⚖ 296 KB

Relative importance of benefits and risk

✍ Yuan, Zhong; Levitan, Bennett; Burton, Paul; Poulos, Christine; Brett Hauber, A. 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 528 KB

Inhibition of Platelet Aggregation by AZ

✍ Robert F. Storey; Steen Husted; Robert A. Harrington; Stanley Heptinstall; Rober 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 797 KB